ASCO 2023 | Gamma signature guidance in optimizing neoadjuvant immunotherapy for resectable melanoma

Minke Lucas, MD, from The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the next steps for researching the optimal neoadjuvant immunotherapy regimen for resectable stage III melanoma based on the interferon gamma signature. The focus is on determining which patients should receive anti-PD-1 monotherapy and which should undergo the neoadjuvant combination regimen. The gamma signature biomarker holds promise in guiding these treatment decisions, ensuring a balanced ratio between treatment efficacy and toxicity. This approach aims to refine the application of immunotherapy in the adjuvant setting and improve patient outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.